Few London-listed businesses sit as squarely at the intersection of agriculture and biotechnology as Genus plc. The Basingstoke-headquartered group supplies genetic material to pig and cattle producers worldwide. In 2025 it crossed a scientific threshold that had eluded the livestock industry for years: regulatory clearance in the United States for a gene-edited pig bred to resist one of the sector's costliest diseases.
The Quick Version
- Genus is a commercial-stage animal genetics company on the LSE Main Market (GNS), a FTSE 250 constituent, with two core divisions: PIC (porcine) and ABS (bovine).
- Its gene-edited PRRS-resistant pig received US FDA approval in April 2025 and Canadian clearance for food use in January 2026, with further export-market approvals still pending.
- FY26 half-year adjusted pre-tax profit rose 57% to £55.7m, and a July 2026 update guided full-year adjusted PBT moderately ahead of consensus.
- A completed China porcine joint venture generated substantial net cash proceeds and cut net leverage to roughly 0.4 times.
- Commercial upside from gene editing is unproven and depends on further regulatory approvals, farmer adoption and pricing.
What Genus Actually Does
Genus develops and sells superior animal genetics, principally to pork, dairy and beef producers, allowing farmers to breed livestock that grow more efficiently, produce more milk or meat, and require fewer inputs. Genus PIC (Pig Improvement Company) supplies porcine genetics and is the larger profit contributor; Genus ABS supplies bovine genetics including bull semen and reproductive technologies. Rather than selling animals directly, Genus typically licenses or sells genetic material, earning royalty-like income as its genetic lines are multiplied through customers' herds.
The Science: From Selective Breeding to Gene Editing
Genus PIC developed a pig genetically edited to resist porcine reproductive and respiratory syndrome (PRRS), an endemic viral disease the industry regards as among the most economically damaging afflictions in pork production. The edit alters a specific gene so the virus can no longer bind to and infect the animal's cells, conferring resistance rather than treating symptoms. This is gene editing, not transgenic modification — changing the pig's own DNA at a targeted location rather than introducing genetic material from another species.
Two Regulatory Wins, More Still Needed
Following US FDA approval in April 2025, Canadian authorities cleared the gene-edited pig for commercial sale as food in January 2026, with favourable determinations reported in several Latin American markets. However, approvals in key export destinations — notably Mexico and Japan — remain outstanding and are, on the company's own account, prerequisites for meaningful North American commercialisation, given the export orientation of US pork.
The China Joint Venture and What It Freed Up
On 31 January 2026, Genus completed a porcine joint venture in China, contributing its China pig business while retaining a 49% stake and receiving substantial net cash proceeds — approximately £111 million, according to the 14 July 2026 trading update — materially strengthening the balance sheet. Because Genus now holds a minority position, PIC China is deconsolidated and contributes as an associate, changing the shape of reported results.
The Numbers
FY2025 (year to 30 June 2025) revenue was £672.8m, up 1% reported (5% constant currency), adjusted operating profit £93.1m (up 19% CC), adjusted pre-tax profit £74.3m (up 24%). Net debt fell to £228.2m (1.5x adjusted EBITDA). Half-year results to 31 December 2025 showed revenue broadly flat at £335.6m, but adjusted operating profit up 38% to £55.8m and adjusted pre-tax profit up 57% to £55.7m, aided by strong PIC trading in China and Latin America and a £5.6m milestone payment from Chinese partner Beijing Capital Agribusiness. Following the China JV proceeds, net leverage fell to around 0.4 times.
The 14 July 2026 update guided full-year adjusted pre-tax profit of approximately £98 million, moderately ahead of consensus.
Risks Worth Weighing
Regulatory risk is central — clearances in Mexico, Japan, China and other markets are pending, with no certainty on timing. Commercialisation risk is equally material, since farmer adoption, supply-chain acceptance and consumer sentiment toward gene-edited food remain unproven at scale. The business is exposed to cyclical end markets including pork and dairy prices, feed costs and animal-disease outbreaks such as African swine fever. The China joint venture introduces partner and jurisdictional dependencies.
What to Watch Next
Preliminary FY26 results due in September 2026, which should clarify the underlying earnings picture after the China deconsolidation. Further regulatory approvals for the PRRS-resistant pig, particularly Mexico and Japan. Evidence of early commercial adoption or licensing arrangements. Progress on the ABS Value Acceleration Programme.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...